|
Sulfametopyrazine
drug data and news
Sulfametopyrazine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Sulfametopyrazine
|
| Brand Names/Synonyms |
AS 18908; Dalysep; F.I. 5978; FI 5978; Farmitalia 204/122; Kelfizin; Kelfizina; Kelfizine; Kelfizine W; Longum; Polycidal; SMP; SMP2; Solfametopirazina [Dcit]; Sulfalen; Sulfalene; Sulfalene [Usan:Inn]; Sulfaleno [Inn-Spanish]; Sulfalenum [Inn-Latin]; Sulfamethopyrazine; Sulfamethoxypyrazine; Sulfamethoxysuccinate; Sulfametopyrazine; Sulfametoxypyridazin; Sulfapyrazinemethoxine; Sulfapyrazinemethoxyine; Sulfapyrazinemethoxyne; WR 4629 |
| Indication |
For the treatment of urinary tract infection and chronic bronchitis |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Sulfametopyrazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. |
| Mechanism Of Action |
Sulfametopyrazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. |
Sulfametopyrazine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Tablet |
| Drug_Category |
Antimalarials; Anti-Infectives; Anti-Infective Agents, Urinary |
| Absorption |
Not Available |
| Interactions |
Drug Interactions:
Sulfametopyrazine increases the effects of the some drugs, including:
ACETOHEXAMIDE
CHLORPROPAMIDE
CLOZAPINE
GLIBENCLAMIDE
GLIBORNURIDE
GLICLAZIDE
GLIMEPIRIDE
GLIPIZIDE
GLIQUIDONE
GLYMIDINE
TOLAZAMIDE
TOLBUTAMIDE
Sulfametopyrazine decreases the effects of the follwing drugs:
ETHINYLESTRADIOL
ORAL CONTRACEPTIVES
POTASSIUM AMINOBENZOATE
|
| Toxicity |
Not Available |
| Organisms Affected |
Not Available |
| Chemical IUPAC Name |
4-amino-N-(3-methoxypyrazin-2-yl)-benzenesulfonamide |
| Chemical Formula |
C11H12N4O3S |
| Molecular Weight |
280.304 g/mol |
| Smiles String |
COC1=NC=CN=C1NS(=O)(=O)C2=CC=C(C=C2)N |
| Melting Point |
169.5 °C |
| Water Solubility |
4030 mg/L |
| State |
Solid |
| LogP/Hphobicity |
1.441 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00517 |
| CAS Registry Number |
152-47-6 |
| KEGG Compound ID |
C12616 |
| PubChem ID |
SID:583006 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
